In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response.
Publication
, Journal Article
Holsinger, T; Riordan, P
Published in: Ann Intern Med
September 2023
Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388:2315-2325. 37224232.
Duke Scholars
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
September 2023
Volume
176
Issue
9
Start / End Page
JC105
Location
United States
Related Subject Headings
- Ketamine
- Humans
- General & Internal Medicine
- Depressive Disorder, Major
- Depression
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Holsinger, T., & Riordan, P. (2023). In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response. Ann Intern Med, 176(9), JC105. https://doi.org/10.7326/J23-0068
Holsinger, Tracey, and Paul Riordan. “In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response.” Ann Intern Med 176, no. 9 (September 2023): JC105. https://doi.org/10.7326/J23-0068.
Holsinger T, Riordan P. In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response. Ann Intern Med. 2023 Sep;176(9):JC105.
Holsinger, Tracey, and Paul Riordan. “In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response.” Ann Intern Med, vol. 176, no. 9, Sept. 2023, p. JC105. Pubmed, doi:10.7326/J23-0068.
Holsinger T, Riordan P. In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response. Ann Intern Med. 2023 Sep;176(9):JC105.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
September 2023
Volume
176
Issue
9
Start / End Page
JC105
Location
United States
Related Subject Headings
- Ketamine
- Humans
- General & Internal Medicine
- Depressive Disorder, Major
- Depression
- 3202 Clinical sciences
- 11 Medical and Health Sciences